GC Cell Set to Participate in the US Cancer Moonshot Project
Initiative aims to reduce cancer mortality rates by 50% in the next 25 years.
GC Cell announced in a company press release that it will be joining CancerX, part of the US Cancer Moonshot project. Started by the Biden administration, the Cancer Moonshot aims to reduce cancer patient mortality rates by over 50% over the next 25 years. According to the company, it aims to highlight the importance and potential of cell therapy in cancer treatment through participating in the initiative.
"I am pleased to contribute to projects that can change the lives of many patients and their families,” said James Park, CEO, GC Cell.” “The Cancer Moonshot & CancerX provides an expanded opportunity to build diverse collaborative research and partnership frameworks with global companies."
Reference: GC Cell Joins US Cancer Moonshot Project. PR Newswire. October 24, 2023. Accessed October 25, 2023. https://www.prnewswire.com/news-releases/gc-cell-joins-us-cancer-moonshot-project-301966721.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
